Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen

PHASE3CompletedINTERVENTIONAL
Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Interferon beta-1b

DRUG

Zidovudine

Trial Locations (25)

10003

Beth Israel Med Ctr / Peter Krueger Clinic, New York

10014

Chelsea Village Med Ctr, New York

10016

Dr Douglas Dieterich, New York

10021

Mem Sloan - Kettering Cancer Ctr, New York

19107

Thomas Jefferson Med College, Philadelphia

19146

Graduate Hosp, Philadelphia

20016

Dr William Davis, Washington D.C.

20037

George Washington Univ Med Ctr, Washington D.C.

21205

Johns Hopkins Hosp, Baltimore

30308

AIDS Research Consortium of Atlanta, Atlanta

33612

Univ of South Florida, Tampa

44106

Univ Hosp of Cleveland / Case Western Reserve Univ, Cleveland

60611

Northwestern Univ Med School, Chicago

60612

Rush Presbyterian - Saint Luke's Med Ctr, Chicago

77550

Univ TX Galveston Med Branch, Galveston

90033

USC School of Medicine / Norris Cancer Hosp, Los Angeles

90048

Cedars Sinai Med Ctr, Los Angeles

90095

UCLA CARE Ctr, Los Angeles

92668

UCI Med Ctr, Orange

94114

Davies Med Ctr, San Francisco

94609

Summitt Med Ctr / San Francisco Gen Hosp, Oakland

94704

Alta Bates / Herrick Hosp, Berkeley

95128

Santa Clara Valley Med Ctr, San Jose

191341095

Saint Christopher's Hosp for Children, Philadelphia

02118

Boston Med Ctr, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Bayer

INDUSTRY

NCT00002238 - Phase III Randomized Double-Blind Placebo Controlled Study To Evaluate the Safety and Efficacy of Betaseron in AIDS and Advanced ARC Patients Receiving a Reduced-Dose AZT Regimen | Biotech Hunter | Biotech Hunter